Degenerative Joint Disease (Osteoarthritis)

Last updated: November 17, 2025

Osteoarthirtis

Osteoarthritis is a chronic, progressive, non-inflammatory degenerative joint disease. It is associated with aging (primary osteoarthritis) though other arthropathies and weight can predispose to osteoarthritis (secondary osteoarthritis). There is loss of articular cartilage with bone remodelling, osteophyte formation, ligamentous laxity, periatricular muscle weakness and synovitis. It most commonly affects the joints of the hands and weight-bearing joints (knees and hips)

SLICE Mnemonic

MnemonicDescription
SystemicNo systemic. Primary osteoarthritis is not associated with systemic symtpoms
LocationsHands (wrists, MCPs, PIPs, DIPs) and weight bearing joints (hips, knees). Not necessarily symmetrical
InflammationJoints are not externally inflammed
ChronicityChronic and progressive. Insidious onset. Worsens with activity, improves with rest. There may be morning stiffness but is shorter than inflammatory arthropathies (< 30 minutes)
Evidence of traumaMay occur secondary to trauma to a specific joint
  • Risk factors
    • Age
    • Obesity
    • Repetitive joint use
    • Inflammatory conditions and arthritides
    • Hemoglobinopathies (sickle cell disease)
    • Metabolic disorders (diabetes mellitus)
    • Congenital and acquired disorders (developmental dysplasia of the hip, traumatic limb deformitites): leads to abnormal joint mechanics
    • Previous surgery (meniscectomy)
    • Genetics
  • Patient history
    • Older patient (> 50 years) with joint pain
    • Overweight (obesity)
    • Repetitive joint work
    • Other arthropathies
  • Signa and symptoms
    • Joint pain
      • Weight-bearing joints or those involved in repetitive activity
      • Worsened with activity
      • Improves with rest
      • Eventually becomes constant
  • Physical examination
    • Normal joints externally
    • Decreased range of motion
    • Crepitus
    • Nodes on the DIPs (Herberden’s) and PIPs (Bouchard’s)
  • Investigations
    • X-ray of the affected joint (weight-bearing): to assess joint space and surrounding bony changes
      • Reduction in joint space
      • Bone spurs
    • Other labs should be normal (CBC, ESR, Rheumatoid Factor and others depending on presentation)
  • Overview of treatment
    • Palliative (reduce pain and maximize function)
    • NSAIDs (ibuprofen, ketoprofen, meloxicam, diclofenac and celecoxib). Add a PPI. Avoid COX-2 inhibitor in patients with a histor of heart disease.
    • Duloxetine or tramadol: second-line
    • Weight loss, exercise, splinting, physical therapy, occupational therapy and hot/cold compression as adjuncts
    • Intra-articular injections
    • Operative treatment (arthroplasty, arthrodesis or osteotomy for severe disease)

Non-operative Treatment

  • Weight loss
    • Weight loss of as little as 5kg decreases the risk of developing knee osteoarthritis in women by 50%
    • Weight loss of 10 kg significantly improves existing symptoms
    • Regular physical activity reduces the incidence of arthritis
  • Activity modification
    • Limit joint stresses in regular activity by decreasing high-impact activities such as running and jumping
  • Rest
    • Resting reduces repetitive microtrauma and promotes healing
  • Steroid injection
    • Corticosteroids with local anaesthesia can be used
  • Others
    • Bracing
    • Physical therapy

Operative Treatment

ProcedureIndication
OsteotomyIsolated medial compartment arthritis in knees aligned in varus
Arthrodesis (joint fusion)Severe arthritis, especially of the ankle
Arthroplasty (joint replacement)End-stage hip and knee degenerative joint disease
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *